SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Procept (PRCT): 50% rise on high volume. Why?
PRCT 30.67-2.1%1:41 PM EST

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: T. Mann who wrote (97)4/14/1997 6:29:00 PM
From: Douglas   of 455
 
Very little is said in the 1996 10K. I had to go back to the 1995 annual report.

Page 4: CD4 is a protein receptor expressed on the surface of a subset of T cells, known as CD4+cells, comprising approximately two-thirds of peripheral T cells. CD4 plays an important role in the modulation of an immune response of CD4+cells that recognize foreign antigens. Stimulation of CD4+cells by foreign antigens presented by the MHC leads to the production of cascade of lymphokines that subsequently enhances the immune response.

Page 6: Procept has identified a compound, PRO 2000, which has been shown, in in vitro studies, to be effective in preventing HIV from binding to CD4 and infecting live human T cells. Studies conducted by the company have demonstrated that PRO 2000 blocks a wide range of laboratory and patient-isolated strains of HIV from infecting both T cells and macrophages, the two major reservoirs for the virus.

PRO 2000 is not a protein or vitamin. The company called it a synthetic molecule. They called CD4 a protein.

I agree, the name is not very scientific. Never seen any explanation. Sounds like a golf club.

Don't know anything about peer reviews. This Company does not release much news. This may be the result of our current legal system. Too many lawsuits!

I agree with Gerald's response.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext